23 results on '"Kickhoefer, Valerie A."'
Search Results
2. A Vault-Encapsulated Enzyme Approach for Efficient Degradation and Detoxification of Bisphenol A and Its Analogues.
- Author
-
Wang, Meng, Chen, Yichang, Kickhoefer, Valerie A., Rome, Leonard H., Allard, Patrick, and Mahendra, Shaily
- Published
- 2019
- Full Text
- View/download PDF
3. Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection
- Author
-
Fulcher, Jennifer A., Tamshen, Kyle, Wollenberg, Alexander L., Kickhoefer, Valerie A., Mrazek, Jan, Elliott, Julie, Ibarrondo, F. Javier, Anton, Peter A., Rome, Leonard H., Maynard, Heather D., Deming, Timothy, and Yang, Otto O.
- Abstract
“Vaults” are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood mononuclear cells (PBMC), predominately dendritic cells, monocytes/macrophages, and activated T cells. As these cell types are the primary targets for human immunodeficiency virus type 1 (HIV-1) infection, we examined the utility of recombinant human vaults for targeted delivery of antiretroviral drugs. We chemically modified three different antiretroviral drugs, zidovudine, tenofovir, and elvitegravir, for direct conjugation to vaults. Tested in infection assays, drug-conjugated vaults inhibited HIV-1 infection of PBMC with equivalent activity to free drugs, indicating vault delivery and drug release in the cytoplasm of HIV-1-susceptible cells. The ability to deliver functional drugs via vault nanoparticle conjugates suggests their potential utility for targeted drug delivery against HIV-1.
- Published
- 2019
- Full Text
- View/download PDF
4. Vault Nanoparticles: Chemical Modifications for Imaging and Enhanced Delivery
- Author
-
Benner, Nancy L., Zang, Xiaoyu, Buehler, Daniel C., Kickhoefer, Valerie A., Rome, Michael E., Rome, Leonard H., and Wender, Paul A.
- Abstract
Vault nanoparticles represent promising vehicles for drug and probe delivery. Innately found within human cells, vaults are stable, biocompatible nanocapsules possessing an internal volume that can encapsulate hundreds to thousands of molecules. They can also be targeted. Unlike most nanoparticles, vaults are nonimmunogenic and monodispersed and can be rapidly produced in insect cells. Efforts to create vaults with modified properties have been, to date, almost entirely limited to recombinant bioengineering approaches. Here we report a systematic chemical study of covalent vault modifications, directed at tuning vault properties for research and clinical applications, such as imaging, targeted delivery, and enhanced cellular uptake. As supra-macromolecular structures, vaults contain thousands of derivatizable amino acid side chains. This study is focused on establishing the comparative selectivity and efficiency of chemically modifying vault lysine and cysteine residues, using Michael additions, nucleophilic substitutions, and disulfide exchange reactions. We also report a strategy that converts the more abundant vault lysine residues to readily functionalizable thiol terminated side chains through treatment with 2-iminothiolane (Traut’s reagent). These studies provide a method to doubly modify vaults with cell penetrating peptides and imaging agents, allowing for in vitrostudies on their enhanced uptake into cells.
- Published
- 2017
- Full Text
- View/download PDF
5. Vault Nanoparticles Packaged with Enzymes as an Efficient Pollutant Biodegradation Technology
- Author
-
Wang, Meng, Abad, Danny, Kickhoefer, Valerie A., Rome, Leonard H., and Mahendra, Shaily
- Abstract
Vault nanoparticles packaged with enzymes were synthesized as agents for efficiently degrading environmental contaminants. Enzymatic biodegradation is an attractive technology for in situcleanup of contaminated environments because enzyme-catalyzed reactions are not constrained by nutrient requirements for microbial growth and often have higher biodegradation rates. However, the limited stability of extracellular enzymes remains a major challenge for practical applications. Encapsulation is a recognized method to enhance enzymatic stability, but it can increase substrate diffusion resistance, lower catalytic rates, and increase the apparent half-saturation constants. Here, we report an effective approach for boosting enzymatic stability by single-step packaging into vault nanoparticles. With hollow core structures, assembled vault nanoparticles can simultaneously contain multiple enzymes. Manganese peroxidase (MnP), which is widely used in biodegradation of organic contaminants, was chosen as a model enzyme in the present study. MnP was incorporated into vaults viafusion to a packaging domain called INT, which strongly interacts with vaults’ interior surface. MnP fused to INT and vaults packaged with the MnP-INT fusion protein maintained peroxidase activity. Furthermore, MnP-INT packaged in vaults displayed stability significantly higher than that of free MnP-INT, with slightly increased Kmvalue. Additionally, vault-packaged MnP-INT exhibited 3 times higher phenol biodegradation in 24 h than did unpackaged MnP-INT. These results indicate that the packaging of MnP enzymes in vault nanoparticles extends their stability without compromising catalytic activity. This research will serve as the foundation for the development of efficient and sustainable vault-based bioremediation approaches for removing multiple contaminants from drinking water and groundwater.
- Published
- 2015
- Full Text
- View/download PDF
6. Polyribosomes Are Molecular 3D Nanoprinters That Orchestrate the Assembly of Vault Particles
- Author
-
Mrazek, Jan, Toso, Daniel, Ryazantsev, Sergey, Zhang, Xing, Zhou, Z. Hong, Fernandez, Beatriz Campo, Kickhoefer, Valerie A., and Rome, Leonard H.
- Abstract
Ribosomes are molecular machines that function in polyribosome complexes to translate genetic information, guide the synthesis of polypeptides, and modulate the folding of nascent proteins. Here, we report a surprising function for polyribosomes as a result of a systematic examination of the assembly of a large ribonucleoprotein complex, the vault particle. Structural and functional evidence points to a model of vault assembly whereby the polyribosome acts like a 3D nanoprinter to direct the ordered translation and assembly of the multi-subunit vault homopolymer, a process which we refer to as polyribosome templating. Structure-based mutagenesis and cell-free in vitroexpression studies further demonstrated the critical importance of the polyribosome in vault assembly. Polyribosome templating prevents chaos by ensuring efficiency and order in the production of large homopolymeric protein structures in the crowded cellular environment and might explain the origin of many polyribosome-associated molecular assemblies inside the cell.
- Published
- 2014
- Full Text
- View/download PDF
7. The Vault Exterior Shell Is a Dynamic Structure that Allows Incorporation of Vault-Associated Proteins into Its Interior.
- Author
-
Poderycki, Michael J., Kickhoefer, Valerie A., Kaddis, Catherine S., Raval-Fernandes, Sujna, Johansson, Erik, Zink, Jeffrey I., Loo, Joseph A., and Rome, Leonard H.
- Published
- 2006
- Full Text
- View/download PDF
8. Bioengineered Vaults: Self-Assembling Protein Shell–Lipophilic Core Nanoparticles for Drug Delivery
- Author
-
Buehler, Daniel C., Marsden, Matthew D., Shen, Sean, Toso, Daniel B., Wu, Xiaomeng, Loo, Joseph A., Zhou, Z. Hong, Kickhoefer, Valerie A., Wender, Paul A., Zack, Jerome A., and Rome, Leonard H.
- Abstract
We report a novel approach to a new class of bioengineered, monodispersed, self-assembling vault nanoparticles consisting of a protein shell exterior with a lipophilic core interior designed for drug and probe delivery. Recombinant vaults were engineered to contain a small amphipathic α-helix derived from the nonstructural protein 5A of hepatitis C virus, thereby creating within the vault lumen a lipophilic microenvironment into which lipophilic compounds could be reversibly encapsulated. Multiple types of electron microscopy showed that attachment of this peptide resulted in larger than expected additional mass internalized within the vault lumen attributable to incorporation of host lipid membrane constituents spanning the vault waist (>35 nm). These bioengineered lipophilic vaults reversibly associate with a sample set of therapeutic compounds, including all-transretinoic acid, amphotericin B, and bryostatin 1, incorporating hundreds to thousands of drug molecules per vault nanoparticle. Bryostatin 1 is of particular therapeutic interest because of its ability to potently induce expression of latent HIV, thus representing a preclinical lead in efforts to eradicate HIV/AIDS. Vaults loaded with bryostatin 1 released free drug, resulting in activation of HIV from provirus latency in vitroand induction of CD69 biomarker expression following intravenous injection into mice. The ability to preferentially and reversibly encapsulate lipophilic compounds into these novel bioengineered vault nanoparticles greatly advances their potential use as drug delivery systems.
- Published
- 2014
- Full Text
- View/download PDF
9. Development of the Vault Particle as a Platform Technology
- Author
-
Rome, Leonard H. and Kickhoefer, Valerie A.
- Abstract
Vaults are naturally occurring nanoparticles found widely in eukaryotes. The particles can be produced in large quantities and are assembled in situfrom multiple copies of the single structural protein following expression. Using molecular engineering, recombinant vaults can be functionally modified and targeted, and their contents can be controlled by packaging. Here, we review the development of engineered vaults as a platform for a wide variety of therapeutic applications and we examine future directions for this unique nanoparticle system.
- Published
- 2013
- Full Text
- View/download PDF
10. Targeted Vault Nanoparticles Engineered with an Endosomolytic Peptide Deliver Biomolecules to the Cytoplasm
- Author
-
Han, Muri, Kickhoefer, Valerie A., Nemerow, Glen R., and Rome, Leonard H.
- Abstract
Vault nanoparticles were engineered to enhance their escape from the endosomal compartment by fusing a membrane lytic peptide derived from adenovirus protein VI (pVI) to the N-terminus of the major vault protein to form pVI-vaults. We demonstrate that these pVI-vaults disrupt the endosomal membrane using three different experimental protocols including (1) enhancement of DNA transfection, (2) co-delivery of a cytosolic ribotoxin, and (3) direct visualization by fluorescence. Furthermore, direct targeting of vaults to specific cell surface epidermal growth factor receptors led to enhanced cellular uptake and efficient delivery of vaults to the cytoplasm. This process was monitored with fluorescent vaults, and morphological changes in the endosomal compartment were observed. By combining targeting and endosomal escape into a single recombinant vault, high levels of transfection efficiency were achieved using low numbers of vault particles. These results demonstrate that engineered vaults are effective, efficient, and nontoxic nanoparticles for targeted delivery of biomaterials to the cell cytoplasm.
- Published
- 2011
- Full Text
- View/download PDF
11. Vaults Are Dynamically Unconstrained Cytoplasmic Nanoparticles Capable of Half Vault Exchange
- Author
-
Yang, Jian, Kickhoefer, Valerie A., Ng, Benny C., Gopal, Ajaykumar, Bentolila, Laurent A., John, Scott, Tolbert, Sarah H., and Rome, Leonard H.
- Abstract
Vaults are naturally occurring ribonucleoprotein particles with an enormous interior volume, large enough to encapsulate hundreds of proteins. They are highly conserved and are present in nearly all eukaryotic cells ranging from 104to 107particles per cell. Recombinant vaults can be produced in vitroand engineered to allow cell targeting and protein packaging. These nanometer-sized particles have many desirable characteristics that may give them advantages for use as drug delivery vehicles. Using photoactivatable green fluorescent protein (PAGFP) labeled vaults, we demonstrate that the particles rapidly diffuse throughout the cytoplasm following single pixel photoactivation in live cells. Their in vivomovement remained relatively unchanged despite exposure to a variety of cellular stresses, suggesting that vaults are largely unconstrained in the cytoplasm. Fluorescence resonance energy transfer (FRET) was observed from polyethylene glycol (PEG) fused hybrid cells that expressed either CFP or YFP labeled vaults, indicating that vaults can exchange major vault protein (MVP) subunits in vivo. Investigation into the mechanism of this exchange in vitrousing recombinant vaults demonstrated that they were capable of rapidly separating at the particle waist and reassembling back into whole vaults, supporting a half vault exchange mechanism. This data suggests a means whereby vaults can functionally interact with their cellular environment and deliver materials packaged within their interior.
- Published
- 2010
- Full Text
- View/download PDF
12. Immobilization of Recombinant Vault Nanoparticles on Solid Substrates
- Author
-
Xia, Yun, Ramgopal, Yamini, Li, Hai, Shang, Lei, Srinivas, Parisa, Kickhoefer, Valerie A., Rome, Leonard H., Preiser, Peter R., Boey, Freddy, Zhang, Hua, and Venkatraman, Subbu S.
- Abstract
Native vaults are nanoscale particles found abundantly in the cytoplasm of most eukaryotic cells. They have a capsule-like structure with a thin shell surrounding a “hollow” interior compartment. Recombinant vault particles were found to self-assemble following expression of the major vault protein (MVP) in a baculovirus expression system, and these particles are virtually identical to native vaults. Such particles have been recently studied as potential delivery vehicles. In this study, we focus on immobilization of vault particles on a solid substrate, such as glass, as a first step to study their interactions with cells. To this end, we first engineered the recombinant vaults by fusing two different tags to the C-terminus of MVP, a 3 amino acid RGD peptide and a 12 amino acid RGD-strep-tag peptide. We have demonstrated two strategies for immobilizing vaults on solid substrates. The barrel-and-cap structure of vault particles was observed for the first time, by atomic force microscopy (AFM), in a dry condition. This work proved the feasibility of immobilizing vault nanoparticles on a material surface, and the possibility of using vault nanoparticles as localized and sustainable drug carriers as well as a biocompatible surface moiety.
- Published
- 2010
- Full Text
- View/download PDF
13. Utilization of a Protein “Shuttle” To Load Vault Nanocapsules with Gold Probes and Proteins
- Author
-
Goldsmith, Lisa E., Pupols, Melody, Kickhoefer, Valerie A., Rome, Leonard H., and Monbouquette, Harold G.
- Abstract
Vaults are large protein nanocapsules that may be useful as drug delivery vehicles due to their normal presence in humans, their large interior volume, their simple structural composition consisting of multiple copies of one protein, and a recombinant production system that also provides a means to tailor their structure. However, for vaults to be effective in such applications, efficient means to load the interiors of the capsules must be demonstrated. Here we describe the use of a domain derived from a vault lumen-associated protein as a carrier to target both gold nanoclusters and heterologous His-tagged proteins to specific binding sites on the vault interior wall.
- Published
- 2009
- Full Text
- View/download PDF
14. Vault Nanoparticles Containing an Adenovirus-Derived Membrane Lytic Protein Facilitate Toxin and Gene Transfer
- Author
-
Lai, Cheng-Yu, Wiethoff, Chris M., Kickhoefer, Valerie A., Rome, Leonard H., and Nemerow, Glen R.
- Abstract
Nonviral methods of gene delivery possess several advantages over that of viral-based vectors, including having increased safety. However, the ability to achieve effective transport of therapeutic molecules across host cell membranes vianonviral methods remains a significant goal. Cell-derived nanoparticles known as vaults have been proposed as novel candidate transfer vehicles for various foreign molecules. Recombinant vault particles enter cells viamacropinocytosis or phagocytosis but lack demonstrable membrane penetrating activity. To explore the feasibility of improving vault penetration into target cells, we incorporated the membrane lytic domain of adenovirus protein VI (pVI) into the interior of recombinant vault particles viafusion to the vault poly(ADP-ribose) polymerase (VPARP) interaction domain. The membrane lytic activity of the pVI domain was retained upon incorporation into vault particles. Moreover, internalization of vault-pVI complexes into murine macrophages promoted co-delivery of a soluble ribotoxin or a cDNA plasmid encoding GFP. These findings indicate that vault particles can be modified to enhance cell transfer of selected biomolecules.
- Published
- 2009
- Full Text
- View/download PDF
15. Targeting Vault Nanoparticles to Specific Cell Surface Receptors
- Author
-
Kickhoefer, Valerie A., Han, Muri, Raval-Fernandes, Sujna, Poderycki, Michael J., Moniz, Raymond J., Vaccari, Dana, Silvestry, Mariena, Stewart, Phoebe L., Kelly, Kathleen A., and Rome, Leonard H.
- Abstract
As a naturally occurring nanocapsule abundantly expressed in nearly all-eukaryotic cells, the barrel-shaped vault particle is perhaps an ideal structure to engineer for targeting to specific cell types. Recombinant vault particles self-assemble from 96 copies of the major vault protein (MVP), have dimensions of 72.5 × 41 nm, and have a hollow interior large enough to encapsulate hundreds of proteins. In this study, three different tags were engineered onto the C-terminus of MVP: an 11 amino acid epitope tag, a 33 amino acid IgG-binding peptide, and the 55 amino acid epidermal growth factor (EGF). These modified vaults were produced using a baculovirus expression system. Our studies demonstrate that recombinant vaults assembled from MVPs containing C-terminal peptide extensions display these tags at the top and bottom of the vault on the outside of the particle and can be used to specifically bind the modified vaults to epithelial cancer cells (A431) viathe epidermal growth factor receptor (EGFR), either directly (EGF modified vaults) or as mediated by a monoclonal antibody (anti-EGFR) bound to recombinant vaults containing the IgG-binding peptide. The ability to target vaults to specific cells represents an essential advance toward using recombinant vaults as delivery vehicles.
- Published
- 2009
- Full Text
- View/download PDF
16. The La RNA-binding protein interacts with the vault RNA and is a vault-associated protein.
- Author
-
Kickhoefer, Valerie A, Poderycki, Michael J, Chan, Edward K L, and Rome, Leonard H
- Abstract
Vaults are highly conserved ubiquitous ribonucleoprotein particles with an undefined function. Three protein species (p240/TEP1, p193/VPARP, and p100/MVP) and a small RNA comprise the 13-MDa vault particle. The expression of the unique 100-kDa major vault protein is sufficient to form the basic vault structure. Previously, we have shown that stable association of the vault RNA with the vault particle is dependent on its interaction with the p240/TEP1 protein. To identify other proteins that interact with the vault RNA, we used a UV-cross-linking assay. We find that a portion of the vault RNA is complexed with the La autoantigen in a separate smaller ribonucleoprotein particle. La interacts with the vault RNA (both in vivo and in vitro) presumably through binding to 3'-uridylates. Moreover, we also demonstrate that the La autoantigen is the 50-kDa protein that we have previously reported as a protein that co-purifies with vaults.
- Published
- 2002
- Full Text
- View/download PDF
17. Assembly of Vault-like Particles in Insect Cells Expressing Only the Major Vault Protein*
- Author
-
Stephen, Andrew G., Raval-Fernandes, Sujna, Huynh, Thu, Torres, Michael, Kickhoefer, Valerie A., and Rome, Leonard H.
- Abstract
Vaults are the largest (13 megadalton) cytoplasmic ribonucleoprotein particles known to exist in eukaryotic cells. They have a unique barrel-shaped structure with 8-fold symmetry. Although the precise function of vaults is unknown, their wide distribution and highly conserved morphology in eukaryotes suggests that their function is essential and that their structure must be important for their function. The 100-kDa major vault protein (MVP) constitutes ∼75% of the particle mass and is predicted to form the central barrel portion of the vault. To gain insight into the mechanisms for vault assembly, we have expressed rat MVP in the Sf9 insect cell line using a baculovirus vector. Our results show that the expression of the rat MVP alone can direct the formation of particles that have biochemical characteristics similar to endogenous rat vaults and display the distinct vault-like morphology when negatively stained and examined by electron microscopy. These particles are the first example of a single protein polymerizing into a non-spherically, non-cylindrically symmetrical structure. Understanding vault assembly will enable us to design agents that disrupt vault formation and hence aid in elucidating vault functionin vivo.
- Published
- 2001
- Full Text
- View/download PDF
18. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance
- Author
-
Siva, Amara C., Raval-Fernandes, Sujna, Stephen, Andrew G., LaFemina, Michael J., Scheper, Rik J., Kickhoefer, Valerie A., and Rome, Leonard H.
- Abstract
Vaults are ribonucleoprotein complexes comprised of the 100 kDa major vault protein (MVP), the 2 high m.w. vault proteins p193 (VPARP) and p240 (TEP1) and an untranslated small RNA (vRNA). Increased levels of MVP, vault-associated vRNA and vaults have been linked directly to non-P-glycoproteinmediated multidrug resistance (MDR). To further characterize the putative role of vaults in MDR, expression levels of all of the vault proteins were examined in various MDR cell lines. Subcellular fractionation of vault particles revealed that all 3 vault proteins are increased in MDR cells compared to the parental, drug-sensitive cells. Furthermore, protein analysis of subcellular fractions of the drug-sensitive, MVP-transfected AC16 cancer cell line indicated that vault levels are increased, in this stable line. Since TEP1 is shared by both vaults and the telomerase complex, TEP1 protein (and vault) levels were compared with telomerase activity in a variety of cell lines, including various MDR lines. Our studies demonstrate that while vault levels may be a good predictor of drug resistance, their up-regulation alone is not sufficient to confer the drug-resistant phenotype. This implies a requirement of an additional factor(s) for vault-mediated MDR. © 2001 Wiley-Liss, Inc.
- Published
- 2001
- Full Text
- View/download PDF
19. Telomerase-Associated Protein TEP1 Is Not Essential for Telomerase Activity or Telomere Length Maintenance In Vivo
- Author
-
Liu, Yie, Snow, Bryan E., Hande, M. Prakash, Baerlocher, Gabriela, Kickhoefer, Valerie A., Yeung, David, Wakeham, Andrew, Itie, Annick, Siderovski, David P., Lansdorp, Peter M., Robinson, Murray O., and Harrington, Lea
- Abstract
TEP1 is a mammalian telomerase-associated protein with similarity to the Tetrahymenatelomerase protein p80. Like p80, TEP1 is associated with telomerase activity and the telomerase reverse transcriptase, and it specifically interacts with the telomerase RNA. To determine the role of mTep1 in telomerase function in vivo, we generated mouse embryonic stem (ES) cells and mice lacking mTep1. ThemTep1-deficient (mTep1−/−) mice were viable and were bred for seven successive generations with no obvious phenotypic abnormalities. All murine tissues from mTep1−/−mice possessed a level of telomerase activity comparable to that in wild-type mice. In addition, analysis of several tissues that normally lack telomerase activity revealed no reactivation of telomerase activity in mTep1−/−mice. Telomere length, even in later generations of mTep1−/−mice, was equivalent to that in wild-type animals. ES cells deficient in mTep1also showed no detectable alteration in telomerase activity or telomere length with increased passage in culture. Thus, mTep1 appears to be completely dispensable for telomerase function in vivo. Recently, TEP1 has been identified within a second ribonucleoprotein (RNP) complex, the vault particle. TEP1 can also specifically bind to a small RNA, vRNA, which is associated with the vault particle and is unrelated in sequence to mammalian telomerase RNA. These results reveal that TEP1 is an RNA binding protein that is not restricted to the telomerase complex and that TEP1 plays a redundant role in the assembly or localization of the telomerase RNP in vivo.
- Published
- 2000
- Full Text
- View/download PDF
20. Telomerase-Associated Protein TEP1 Is Not Essential for Telomerase Activity or Telomere Length Maintenance In Vivo
- Author
-
Liu, Yie, Snow, Bryan E., Hande, M. Prakash, Baerlocher, Gabriela, Kickhoefer, Valerie A., Yeung, David, Wakeham, Andrew, Itie, Annick, Siderovski, David P., Lansdorp, Peter M., Robinson, Murray O., and Harrington, Lea
- Abstract
ABSTRACTTEP1 is a mammalian telomerase-associated protein with similarity to the Tetrahymenatelomerase protein p80. Like p80, TEP1 is associated with telomerase activity and the telomerase reverse transcriptase, and it specifically interacts with the telomerase RNA. To determine the role of mTep1 in telomerase function in vivo, we generated mouse embryonic stem (ES) cells and mice lacking mTep1. ThemTep1-deficient (mTep1-/-) mice were viable and were bred for seven successive generations with no obvious phenotypic abnormalities. All murine tissues frommTep1-/-mice possessed a level of telomerase activity comparable to that in wild-type mice. In addition, analysis of several tissues that normally lack telomerase activity revealed no reactivation of telomerase activity in mTep1-/-mice. Telomere length, even in later generations ofmTep1-/-mice, was equivalent to that in wild-type animals. ES cells deficient in mTep1also showed no detectable alteration in telomerase activity or telomere length with increased passage in culture. Thus, mTep1 appears to be completely dispensable for telomerase function in vivo. Recently, TEP1 has been identified within a second ribonucleoprotein (RNP) complex, the vault particle. TEP1 can also specifically bind to a small RNA, vRNA, which is associated with the vault particle and is unrelated in sequence to mammalian telomerase RNA. These results reveal that TEP1 is an RNA binding protein that is not restricted to the telomerase complex and that TEP1 plays a redundant role in the assembly or localization of the telomerase RNP in vivo.
- Published
- 2000
- Full Text
- View/download PDF
21. Vaults and Telomerase Share a Common Subunit, TEP1*
- Author
-
Kickhoefer, Valerie A., Stephen, Andrew G., Harrington, Lea, Robinson, Murray O., and Rome, Leonard H.
- Abstract
Vaults are large cytoplasmic ribonucleoprotein complexes of undetermined function. Mammalian vaults have two high molecular mass proteins of 193 and 240 kDa. We have identified a partial cDNA encoding the 240-kDa vault protein and determined it is identical to the mammalian telomerase-associated component, TEP1. TEP1 is the mammalian homolog of the Tetrahymenap80 telomerase protein and has been shown to interact specifically with mammalian telomerase RNA and the catalytic protein subunit hTERT. We show that while TEP1 is a component of the vault particle, vaults have no detectable telomerase activity. Using a yeast three-hybrid assay we demonstrate that several of the human vRNAs interact in a sequence-specific manner with TEP1. The presence of 16 WD40 repeats in the carboxyl terminus of the TEP1 protein is a convenient number for this protein to serve a structural or organizing role in the vault, a particle with eight-fold symmetry. The sharing of the TEP1 protein between vaults and telomerase suggests that TEP1 may play a common role in some aspect of ribonucleoprotein structure, function, or assembly.
- Published
- 1999
- Full Text
- View/download PDF
22. The sequence of a cDNA encoding the major vault protein from Rattus norvegicus
- Author
-
Kickhoefer, Valerie A. and Rome, Leonard H.
- Abstract
We have isolated a cDNA clone encoding the 104-kDa major vault protein (MVP) from Rattus norvegicus. The complete nucleotide sequence was determined. Comparison of the deduced amino acid (aa) sequence to that of MvpA from Dictyostelium discoideumrevealed that the proteins share about 57% aa identity. Southern blot analysis indicates that the rat MVP is a single-copy gene.
- Published
- 1994
- Full Text
- View/download PDF
23. Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines*
- Author
-
Kickhoefer, Valerie A., Rajavel, Kavitha S., Scheffer, George L., Dalton, William S., Scheper, Rik J., and Rome, Leonard H.
- Abstract
Vaults are 13-MDa ribonucleoprotein particles composed largely of a 104-kDa protein, termed major vault protein or MVP, and a small vault RNA, vRNA. While MVP levels have been found to increase up to 15-fold in non-P-glycoprotein multidrug-resistant cell lines, the levels of vault particles have not been investigated. As both the function of vault particles and the mechanism of drug resistance in non-P-glycoprotein cells are unknown, we decided to determine whether vault synthesis was coupled to MDR. By cloning the human gene for vRNA and careful quantitation of the MVP and vRNA levels in MDR cells, we find that vRNA is in considerable excess to MVP. Sedimentation measurements of vault particles in multidrug resistance cells have indeed revealed up to a 15-fold increase in vault synthesis, coupled with a comparable shift of associated vRNA, demonstrating that vault formation is limited by expression of MVP or the minor vault proteins. The observation that vault synthesis is linked directly to multidrug resistance supports a direct role for vaults in drug resistance.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.